These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

221 related items for PubMed ID: 30097503

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Integration of (68)Ga-PSMA-PET imaging in planning of primary definitive radiotherapy in prostate cancer: a retrospective study.
    Dewes S, Schiller K, Sauter K, Eiber M, Maurer T, Schwaiger M, Gschwend JE, Combs SE, Habl G.
    Radiat Oncol; 2016 May 26; 11():73. PubMed ID: 27229485
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [68Ga]PSMA-11 for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer.
    Clore J, Scott PJH.
    Expert Rev Mol Diagn; 2024 Jul 26; 24(7):565-582. PubMed ID: 39054633
    [Abstract] [Full Text] [Related]

  • 25. In vitro and in vivo comparative study of a novel 68Ga-labeled PSMA-targeted inhibitor and 68Ga-PSMA-11.
    Chen H, Cai P, Feng Y, Sun Z, Wang Y, Chen Y, Zhang W, Liu N, Zhou Z.
    Sci Rep; 2021 Sep 27; 11(1):19122. PubMed ID: 34580375
    [Abstract] [Full Text] [Related]

  • 26. Preclinical Comparative Study of (68)Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA.
    Ray Banerjee S, Chen Z, Pullambhatla M, Lisok A, Chen J, Mease RC, Pomper MG.
    Bioconjug Chem; 2016 Jun 15; 27(6):1447-55. PubMed ID: 27076393
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Lys-urea-Aad, Lys-urea-Cmc and Lys-urea-Cms as potential pharmacophores for the design of PSMA-targeted radioligands to reduce off-target uptake in kidneys and salivary glands.
    Kuo HT, Zhang Z, Zhang C, Merkens H, Tan R, Wong AAWL, Uribe CF, Bénard F, Lin KS.
    Theranostics; 2023 Jun 15; 13(13):4559-4573. PubMed ID: 37649602
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Synthesis and Initial Biological Evaluation of Boron-Containing Prostate-Specific Membrane Antigen Ligands for Treatment of Prostate Cancer Using Boron Neutron Capture Therapy.
    Wang S, Blaha C, Santos R, Huynh T, Hayes TR, Beckford-Vera DR, Blecha JE, Hong AS, Fogarty M, Hope TA, Raleigh DR, Wilson DM, Evans MJ, VanBrocklin HF, Ozawa T, Flavell RR.
    Mol Pharm; 2019 Sep 03; 16(9):3831-3841. PubMed ID: 31381351
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Synthesis and Evaluation of 68Ga- and 177Lu-Labeled (R)- vs (S)-DOTAGA Prostate-Specific Membrane Antigen-Targeting Derivatives.
    Zhao R, Ploessl K, Zha Z, Choi S, Alexoff D, Zhu L, Kung HF.
    Mol Pharm; 2020 Dec 07; 17(12):4589-4602. PubMed ID: 33108189
    [Abstract] [Full Text] [Related]

  • 35. Enhancing Treatment Efficacy of 177Lu-PSMA-617 with the Conjugation of an Albumin-Binding Motif: Preclinical Dosimetry and Endoradiotherapy Studies.
    Kuo HT, Merkens H, Zhang Z, Uribe CF, Lau J, Zhang C, Colpo N, Lin KS, Bénard F.
    Mol Pharm; 2018 Nov 05; 15(11):5183-5191. PubMed ID: 30251544
    [Abstract] [Full Text] [Related]

  • 36. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Nov 05; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice.
    Kim SB, Song IH, Song YS, Lee BC, Gupta A, Lee JS, Park HS, Kim SE.
    Sci Rep; 2021 Jul 27; 11(1):15263. PubMed ID: 34315965
    [Abstract] [Full Text] [Related]

  • 40. Improving Theranostic Gallium-68/Lutetium-177-Labeled PSMA Inhibitors with an Albumin Binder for Prostate Cancer.
    Lee BS, Kim MH, Chu SY, Jung WJ, Jeong HJ, Lee K, Kim HS, Kim MH, Kil HS, Han SJ, Lee YJ, Lee KC, Lim SM, Chi DY.
    Mol Cancer Ther; 2021 Dec 27; 20(12):2410-2419. PubMed ID: 34725194
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.